Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations

NCT04320888 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04320888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04320888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 3, 2021
Completion date
June 30, 2027
Enrollment
1 (actual)
Sites
174

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphatic system neoplasm, recurrent ependymoma, recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent histiocytic and dendritic cell neoplasm, recurrent langerhans cell histiocytosis, recurrent lymphoma, recurrent malignant germ cell tumor, recurrent malignant glioma, recurrent malignant solid neoplasm, recurrent medulloblastoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent peripheral primitive neuroectodermal tumor, recurrent rhabdoid tumor, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, recurrent who grade 2 glioma, refractory ependymoma, refractory ewing sarcoma, refractory hepatoblastoma, refractory histiocytic and dendritic cell neoplasm, refractory langerhans cell histiocytosis, refractory lymphoma, refractory malignant germ cell tumor, refractory malignant glioma, refractory malignant solid neoplasm, refractory medulloblastoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory peripheral primitive neuroectodermal tumor, refractory rhabdoid tumor, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, refractory who grade 2 glioma, wilms tumor